Latest News
Neurocrine Biosciences, Inc.
- Neurocrine Biosciences starts Alzheimer's Phase 2 trial
- Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment
- Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
- Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
- Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
- Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
- Ruder Finn Wins Neurocrine Biosciences US AOR
- Neurocrine Biosciences names Eiry Roberts as chief medical officer By Investing.com
- Neurocrine Biosciences selects Ruder Finn as communications AOR
- Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
- Neurocrine Biosciences names Eiry W. Roberts as Chief Medical Officer, replacing Sanjay Keswani.
Headlines from the last 30 days, linking to the original publishers. See all market news →